Search
Amiodarone
go.drugbank.com/drugs/DB01118ApprovedInvestigationalAmiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings.
Categories: Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic IndexProducts: AMIODARONA 150 MG/ 3 ML, CORDARONE INJECTION 150 mg/3 mlCefditoren
go.drugbank.com/drugs/DB01066ApprovedCefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Products: CEFITEN 200 MG FILM TABLET, 10 ADET, MEIACT 200 MG FILM TABLET, 10 ADETKetoconazole
go.drugbank.com/drugs/DB01026ApprovedInvestigationalKetoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections. … [A188054] At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption.
Mixtures: CLINDAMICINA/KETOCONAZOL 100 MG/400MGCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsKetamine
go.drugbank.com/drugs/DB01221ApprovedInvestigationalVet approvedKetamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: KETAMINE HAMELN INJECTION 50 MG/ML, KETAX 500 MG/10 ML ENJEKSİYONLUK/ İNFÜZYONLUK ÇÖZELTİ, 1 ADETSapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationalSapropterin (tetrahydrobiopterin or BH4) is a cofactor in the synthesis of nitric oxide. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of
Synonyms: (6R)-L-erythro-tetrahydrobiopterin, 6R-L-5,6,7,8-tetrahydrobiopterinProducts: KUVAN® 100 MG, KUVAN 100 MG ÇÖZÜNEBİLİR TABLET, 120 ADETTirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[L48766] On September 15, 2022, tirzepatide was also approved by the European Commission.[L44386]. On November 02, 2023, tirzepatide was also approved by the Health Canada [L52800] … [A246260] Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety.
Categories: Receptors, G-Protein-CoupledProducts: Mounjaro 15 mg solution for injection in vial, Mounjaro 15 mg/0,5 ml Enjeksiyonluk Çözelti, 1 ADETRituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalFDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes.
Products: MABTHERA SOLUCION PARA INFUSION 10 MG/ML, NOVEX 100 MG/10 ML I.V. İNFÜZYONLUK ÇÖZELTİ İÇİN KONSANTRE, 2 FLAKONEtravirine
go.drugbank.com/drugs/DB06414ApprovedInvestigationalOn March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. … Patients are advised to immediately contact their healthcare provider if a rash develops.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: INTELENCE 100 MG TABLET, 120 ADET, INTELENCE 100 MG TABLETSTreprostinil
go.drugbank.com/drugs/DB00374ApprovedInvestigational[L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin that significantly increases patients' quality of life. … Treprostinil is a stable tricyclic analogue of prostacyclin[A248770] that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesProducts: TIMERAXONE ® 10 MG/ML, REMODULIN 10 mg/ml InfusionslösungVenetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells [A40022]. … Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label].
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VENCLYXTO 10 MG FILM KAPLI TABLET, 10 ADET, VENCLYXTO 10 MG FILM KAPLI TABLET, 14 ADET